Loading...
XNYS
MRK
Market cap226bUSD
Mar 31, Last price  
89.81USD
1D
0.65%
1Q
-9.72%
Jan 2017
52.56%
Name

Merck & Co Inc

Chart & Performance

D1W1MN
P/E
13.25
P/S
3.54
EPS
6.78
Div Yield, %
2.57%
Shrs. gr., 5y
-0.30%
Rev. gr., 5y
6.50%
Revenues
64.17b
+6.74%
22,011,900,00022,636,000,00024,197,700,00023,850,300,00027,428,300,00045,987,000,00048,047,000,00047,267,000,00044,033,000,00042,237,000,00039,498,000,00039,807,000,00040,122,000,00042,294,000,00046,840,000,00041,518,000,00048,704,000,00059,283,000,00060,115,000,00064,168,000,000
Net income
17.12b
+4,589.59%
4,631,300,0004,433,800,0003,275,400,0007,808,400,00012,901,300,000861,000,0006,272,000,0006,661,000,0004,404,000,00011,920,000,0004,442,000,0005,691,000,0002,568,000,0006,220,000,0009,843,000,0007,067,000,00013,049,000,00014,519,000,000365,000,00017,117,000,000
CFO
21.47b
+65.06%
7,608,500,0006,765,200,0006,999,200,0006,571,700,0003,392,000,00010,822,000,00012,383,000,00010,022,000,00011,654,000,0007,860,000,00012,421,000,00010,376,000,0006,447,000,00010,922,000,00013,440,000,00010,253,000,00014,109,000,00019,095,000,00013,006,000,00021,468,000,000
Dividend
Sep 16, 20240.77 USD/sh
Earnings
Apr 24, 2025

Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
URL
https://www.merck.com/
IPO date
Jan 01, 1941
Employees
67,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
64,168,000
6.74%
60,115,000
1.40%
59,283,000
21.72%
Cost of revenue
30,227,000
57,161,000
41,001,000
Unusual Expense (Income)
NOPBT
33,941,000
2,954,000
18,282,000
NOPBT Margin
52.89%
4.91%
30.84%
Operating Taxes
2,803,000
1,512,000
1,918,000
Tax Rate
8.26%
51.18%
10.49%
NOPAT
31,138,000
1,442,000
16,364,000
Net income
17,117,000
4,589.59%
365,000
-97.49%
14,519,000
11.27%
Dividends
(7,840,000)
(7,445,000)
(7,012,000)
Dividend yield
3.10%
2.68%
2.49%
Proceeds from repurchase of equity
(1,306,000)
(1,346,000)
BB yield
0.52%
0.48%
Debt
Debt current
2,649,000
1,657,000
1,946,000
Long-term debt
34,462,000
35,539,000
29,758,000
Deferred revenue
Other long-term liabilities
6,465,000
7,864,000
8,323,000
Net debt
22,959,000
29,851,000
17,497,000
Cash flow
Cash from operating activities
21,468,000
13,006,000
19,095,000
CAPEX
(3,372,000)
(3,863,000)
(4,388,000)
Cash from investing activities
(7,734,000)
(14,083,000)
(4,960,000)
Cash from financing activities
(7,032,000)
(4,810,000)
(9,119,000)
FCF
56,077,000
(5,074,000)
14,694,000
Balance
Cash
13,689,000
7,093,000
13,192,000
Long term investments
463,000
252,000
1,015,000
Excess cash
10,943,600
4,339,250
11,242,850
Stockholders' equity
44,502,000
50,576,000
58,168,000
Invested Capital
39,181,400
77,427,750
71,843,150
ROIC
53.41%
1.93%
22.51%
ROCE
65.89%
3.57%
21.54%
EV
Common stock shares outstanding
2,541,000
2,547,000
2,542,000
Price
99.48
-8.75%
109.02
-1.74%
110.95
44.77%
Market cap
252,778,680
-8.97%
277,673,940
-1.55%
282,034,900
45.00%
EV
275,737,680
307,578,940
299,598,900
EBITDA
38,440,000
6,826,000
22,191,000
EV/EBITDA
7.17
45.06
13.50
Interest
1,146,000
962,000
Interest/NOPBT
38.79%
5.26%